STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice | Science Signaling
Liver tumor growth in mice is exacerbated by a feed-forward loop triggered by the palmitoylation of STAT3. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - December 5, 2023 Category: Science Source Type: news
Drug Trials Snapshots: IMJUDO
IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 29, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
Elecsys ® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory results and clinical information.The single test will inform clinicians if treatment is required and regimens are working in conjunction with other diagnostic assays.Almost 300 million people globally have chronic hepatitis B, causing a significant burden to health systems as it puts patients at high risk of death from cirrhosis and liver cancer.1Basel, 27 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the la...
Source: Roche Media News - November 27, 2023 Category: Pharmaceuticals Source Type: news
Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 -- Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting, the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2023 Category: Pharmaceuticals Source Type: news
Increasing Generational Status Linked to Elevated Risk for Liver Cancer
MONDAY, Nov. 20, 2023 -- For Mexican Americans, increasing generational status is associated with an increased risk for hepatocellular carcinoma (HCC), according to a study published online Nov. 20 in Cancer.Nicholas Acuna, M.P.H., from the Keck... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2023 Category: Pharmaceuticals Source Type: news
Road to RSNA 2023: Ultrasound
Ultrasound's utility will be on full display at this year's RSNA annual meeting, showing its merit in a wide variety of clinical applications. Research to be presented at the annual meeting in Chicago will explore the modality's clinical applications in musculoskeletal, pediatric, abdominal, and women's imaging among other areas. This includes advancements in ultrasound in recent years, such as the use of contrast for improved imaging, elastography and color Doppler for assessing complex pathologies, and using imaging data in AI models. Studies will also evaluate ways to further improve the modality's capabilities by rea...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 2023 Ultrasound Preview Source Type: news
Ultrasound model predicts liver cancer risk
Thursday, November 30 | 2:20 p.m.-2:30 p.m. | R6-SSGI19-6 | Room E352A model integrating clinical and surveillance ultrasound features for patients at high risk of hepatocellular carcinoma will be presented in this session.In his talk, Yeun-Yoon Kim, MD, from Yonsei University in South Korea will present research that demonstrates how this model has superior performance compared with previously reported risk scoring systems in this area.Predicting risk for hepatocellular carcinoma would help with triaging and strategizing best treatment options. Models integrating ultrasound features are being developed to help with suc...
Source: AuntMinnie.com Headlines - November 14, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: 2023 Ultrasound Preview Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Features found on MRI may predict liver cancer recurrence after surgery
An algorithm based on MRI features could help clinicians predict liver cancer recurrence after patients have undergone liver resection, researchers have found.
The findings could translate into better patient outcomes, wrote a team led by Hanyu Jiang, PhD, of West China Hospital, Sichuan University, in Chengdu, China. The study results were published November 7 in Radiology.
"Identifying patients at high risk for advanced-stage hepatocellular carcinoma recurrence after liver resection may improve patient survival," the group noted.
Liver resection is a common treatment for hepatocellular carcinoma, but its long-term eff...
Source: AuntMinnie.com Headlines - November 8, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News Imaging Informatics MRI Artificial Intelligence Genitourinary Radiology Source Type: news
Abdominal fat CT radiomics help predict liver cancer recurrence
This study established pre- and postoperative nomograms incorporating radiomics based on abdominal adipose and muscle tissues to enable the risk stratification of patients with hepatocellular carcinoma for early recurrence," wrote a team led by Shuo Shi, PhD, of Qilu Hospital of Shandong University in China. The group's findings were published October 28 in Academic Radiology.Liver cancer is the third leading cause of cancer-related deaths around the world, and its five-year survival rate is about 18%, the team noted. Although surgical resection is widely used to treat liver cancer, there is a high incidence of postoperati...
Source: AuntMinnie.com Headlines - October 31, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News CT Advanced Visualization Abdominal Imaging Source Type: news
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, …
(Source: Reuters: Health)
Source: Reuters: Health - October 21, 2023 Category: Consumer Health News Source Type: news
Tempest Therapeutics stock soars 4,000% on updated data (NASDAQ:TPST)
Shares of Tempest Therapeutics (NASDAQ:TPST) closed nearly 4,000% higher Wednesday after the company released updated data from a Phase 1/2 study of its drug TPST-1120 in the first-line treatment of advanced or metastatic hepatocellular carcinoma, a type of liver cancer. The stock closed at $9.77…#tempesttherapeutics #tempest #tpst1120 #roche #otcqx #rhhby #morpheus (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2023 Category: Consumer Health News Source Type: news
Dynamic Risk Assessment for HCC in Patients With Chronic HCV Dynamic Risk Assessment for HCC in Patients With Chronic HCV
The authors developed a model for identifying hepatocellular carcinoma risk factors in individuals with chronic HCV, across antiviral treatment status and interactions with cirrhosis.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 20, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
